Caseware UK (AP4) 2023.0.135 2023.0.135 trueNo description of principal activity2023-02-17false40falseThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 14670245 2023-02-16 14670245 2023-02-17 2024-02-28 14670245 2022-02-17 2023-02-16 14670245 2024-02-28 14670245 c:Director1 2023-02-17 2024-02-28 14670245 d:CurrentFinancialInstruments 2024-02-28 14670245 d:CurrentFinancialInstruments d:WithinOneYear 2024-02-28 14670245 d:ShareCapital 2024-02-28 14670245 d:RetainedEarningsAccumulatedLosses 2024-02-28 14670245 c:OrdinaryShareClass1 2023-02-17 2024-02-28 14670245 c:OrdinaryShareClass1 2024-02-28 14670245 c:FRS102 2023-02-17 2024-02-28 14670245 c:AuditExempt-NoAccountantsReport 2023-02-17 2024-02-28 14670245 c:FullAccounts 2023-02-17 2024-02-28 14670245 c:PrivateLimitedCompanyLtd 2023-02-17 2024-02-28 14670245 e:PoundSterling 2023-02-17 2024-02-28 iso4217:GBP xbrli:shares xbrli:pure

Registered number: 14670245










Dloc Biosystems Limited








Unaudited

Financial statements

Information for filing with the registrar

For the period ended 28 February 2024

 
Dloc Biosystems Limited
Registered number: 14670245

Balance sheet
As at 28 February 2024

2024
Note
£

  

Current assets
  

Debtors: amounts falling due within one year
 4 
13,793

Cash at bank and in hand
  
6,207

  
20,000

Creditors: amounts falling due within one year
 5 
(166,500)

Net current (liabilities)/assets
  
 
 
(146,500)

Total assets less current liabilities
  
(146,500)

  

Net (liabilities)/assets
  
(146,500)


Capital and reserves
  

Called up share capital 
 6 
1

Profit and loss account
  
(146,501)

  
(146,500)


The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 14 November 2024.




W Malaeb
Director

The notes on pages 2 to 5 form part of these financial statements.
Page 1

 
Dloc Biosystems Limited
 

 
Notes to the financial statements
For the period ended 28 February 2024

1.


General information

Dloc Biosystems Limited is a private company limited by shares and incorporated in England with company number 14670245. The registered office is Innovation House, Innovation Way, Discovery Park, Sandwich, Kent, CT13 9FF.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The financial statements are rounded to the nearest pound.

The following principal accounting policies have been applied:

 
2.2

Going concern

The director has a reasonable expectation that the company has adequate resources to continue in operational existence for the forseeable future. Thus they continue to adopt the going concern basis in preparing the annual financial statements.

 
2.3

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of income and retained earnings within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

 
2.4

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Page 2

 
Dloc Biosystems Limited
 

 
Notes to the financial statements
For the period ended 28 February 2024

2.Accounting policies (continued)

 
2.5

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.6

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

The Company has elected to apply the recognition and measurement provisions of IFRS 9 Financial Instruments (as adopted by the UK Endorsement Board) with the disclosure requirements of Sections 11 and 12 and the other presentation requirements of FRS 102.

Financial instruments are recognised in the Company's Balance sheet when the Company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include trade and other debtors, cash and bank balances, are initially measured at their transaction price (adjusted for transaction costs except in the initial measurement of financial assets that are subsequently measured at fair value through profit and loss) and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other debtors due with the operating cycle fall into this category of financial instruments.

Other financial assets

Other financial assets, which includes investments in equity instruments which are not classified as subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the recognised transaction price. Such assets are subsequently measured at fair value with the changes in fair value being recognised in the profit or loss. Where other financial assets are not publicly traded, hence their fair value cannot be measured reliably, they are measured at cost less impairment.






 
Page 3

 
Dloc Biosystems Limited
 

 
Notes to the financial statements
For the period ended 28 February 2024

2.Accounting policies (continued)


2.6
Financial instruments (continued)


Financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other creditors, bank loans and other loans are initially measured at their transaction price (adjusting for transaction costs except in the initial measurement of financial liabilities that are subsequently measured at fair value through profit and loss). When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future payments discounted at a market rate of interest, discounting is omitted where the effect of discounting is immaterial.

Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.

Trade creditors are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade creditors are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.


3.


Employees

The average monthly number of employees, including directors, during the period was 4.


4.


Debtors

2024
£


Dloc Biosystems AS Intercompany
2,680

Other debtors
2,713

Prepayments and accrued income
8,400

13,793



5.


Creditors: Amounts falling due within one year

2024
£

Trade creditors
5,409

Amounts owed to other associated companies
158,591

Accruals and deferred income
2,500

166,500


Page 4

 
Dloc Biosystems Limited
 

 
Notes to the financial statements
For the period ended 28 February 2024

6.


Share capital

2024
£
Allotted, called up and fully paid


1 Ordinary share of £1.00
1





7.


Related party transactions

All related party transactions during the current period, including key management personnel compensation were made under normal market conditions.


8.


Controlling party

The ultimate controlling party is Dloc Biosystems Inc, with 100% shareholding.

Page 5